U.S. stock futures slightly higher after Christmas holiday
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- Wall St slips as higher Treasury yields weigh on sentiment
- Oil pares losses as market weighs Saudi supply concerns, Middle East tensions
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Ionis Pharmaceuticals (IONS) PT Raised to $68 at BMO Capital
December 28, 2016 3:55 PM ESTBMO Capital analyst Do Kim reiterated an Outperform rating and rasied his price target on Ionis Pharmaceuticals (NASDAQ: IONS) to $68.00 (from $61.00) as the firm's Spinraza estimates increase to reflect a faster ramp based on the broad approval and a higher price point... More
Ionis Pharmaceuticals (IONS) Spinraza Approval Expected But a 'Major Positive', Laidlaw Says; PT Up To $65
December 27, 2016 9:31 AM ESTLaidlaw analyst Yale Jen reiterated a Buy rating and raised its price target on Ionis Pharmaceuticals (NASDAQ: IONS) to of $65.00 (from $59.00) announced the FDA approved Spinraza as a spinal muscular atrophy (SMA) treatment in pediatric and adult (late-onset) patients. IONS earned a... More
Needham & Company Reiterates Buy on Ionis Pharmaceuticals (IONS) Following FDA Approval
December 27, 2016 9:26 AM ESTNeedham & Company analyst Chad Messer reiterated a Buy rating and $64 price target on Ionis Pharmaceuticals (NASDAQ: IONS) and partner Biogen were granted FDA approval for SPINRAZA (nusinersen), a treatment for spinal muscular atrophy. SPINRAZA will have a broad label including both children and adults... More
